logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Observational studies with drugs published in the Spanish Trial Registry

 

Source: www.actasanitaria.com

The Spanish Agency for Medicines and Health Products (AEMPS) has communicated that Royal Decree 957/2020, of November 3, which regulates observational studies with drugs for human use, in force since January 2, provides for the Publication in the Spanish Registry of clinical studies (REec) of the information on observational studies with drugs (EOm) carried out in Spain.

This regulation establishes that “it is the responsibility of the promoter of the observational study with drugs to carry out the publication of the study in REec”, as well as that “the publication of information in the REec is mandatory for observational studies with prospective and voluntary follow-up drugs for the rest of these studies ”.

In turn, this text states that, “at the beginning of the study, information must be published, at least on the title, the promoter, the drugs under study, the main objective and the sources of funding. This information will be updated in the event of substantial modifications throughout the study ”.

“Once the study is completed, the promoter will provide information on the results obtained, both positive and negative, either through a summary of the results or through a bibliographic reference of the scientific publication that contains them,” argues Royal Decree 957/2020.

With the GESTO telematics platform
To date, only the inclusion in the REec of information from clinical trials with drugs was enabled; From now on, it is possible to record information on the EOm, through the telematics platform GESTO (Management of Observational Studies with medicines), launched by the AEMPS. This telematics platform is available from this Wednesday, April 14.

Also, this Agency remarks that “registration is voluntary for EOs that are not prospective follow-up, their inclusion in the REec will allow researchers to identify synergies in their research lines and promote future collaborations between research teams.”

Royal Decree 957/2020 provides that the AEMPS publishes instructions in which the procedures, deadlines and the format of the data that the REec will include are indicated. These instructions are available on the website of this Agency in Observational Studies with Medicines for Human Use, under the heading New regulations in force as of January 2.

Related entries

2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más
19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más

Recent Posts

  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.